The global tachycardia drugs market is expected to witness significant growth during the forecast period. Cardiovascular diseases are one of the foremost causes of death globally. Factors such as increasing approvals for vascular closure devices, increasing demand for advanced treatment, increasing research and clinical trials for tachycardia, government initiatives and support, and rising market players offering newer products are likely to boost the market. Many major market players are contributing a lot in drug discovery and development. COVID-19 also had a major impact on the market growth.
Key Growth Drivers
- Increase in Cardiovascular Diseases
According to the WHO, around 60% - 85% of population have adopted a sedentary life. According to CDC, approximately 31 million adults aged over 50 years lives a sedentary life, and only 1 out of 4 U.S. adults meets the appropriate need of physical activity. As a result, inotropic agents are used in this process. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
The report outlines the involvement of key players, including:
Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Boehringer Ingelheim International GmbH. (Germany), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Cadila Pharmaceuticals (India), Lilly (U.S.), Cipla Inc. (U.S.), Aurobindo Pharma (India), Lupin (India), ADVANZ PHARMA (U.K.), Avet Pharmaceuticals Inc. (U.S.)
Key Market Segmentation
Drugs (Lanoxin, Tapazole, Acetaminophen, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
Know More about This Premium Research Report @ https://www.databridgemarketresearch.com/reports/global-tachycardia-drugs-market
Browse More Reports:
https://www.databridgemarketresearch.com/reports/global-mycophenolate-market
https://www.databridgemarketresearch.com/reports/global-anti-money-laundering-market
https://www.databridgemarketresearch.com/reports/europe-anti-money-laundering-market
https://www.databridgemarketresearch.com/reports/asia-pacific-anti-money-laundering-market
About Data Bridge Market Research, Private Ltd
Data Bridge Market Research is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe.
Contact Us
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email – [email protected]
